Berlin, Germany
Nostos Genomics, founded in 2018, is revolutionizing the field of genetic diagnostics by transforming data into actionable genomic insights. Operating at the intersection of AI, Biotechnology, and Machine Learning, this Germany-based startup provides genetic testing labs with a CE-certified platform designed to streamline the interpretation of genetic mutations. Their platform significantly reduces the time and cost associated with diagnosing genetic diseases, addressing a critical bottleneck in the process, where up to 70% of tests remain inconclusive.
The company has identified a vast market opportunity, with over 300 million people worldwide living with rare genetic diseases and facing diagnostic odysseys that can last years. By automating mutation interpretation, Nostos Genomics empowers labs to deliver faster, more accurate diagnoses and facilitates the development of targeted therapies.
With a recent €5.00M Seed Round in February 2022, spearheaded by investors like Entrepreneur First, Frontline Ventures, and others, the company is poised to scale and enhance its impact on genetic testing globally.
